Overview

Study to Compare Pioglitazone and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus and Dyslipidemia

Status:
Completed
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
Efficacy comparison of Pioglitazone, once daily (QD), to Rosiglitazone in participants with Type 2 Diabetes
Phase:
Phase 3
Details
Lead Sponsor:
Takeda
Collaborator:
Eli Lilly and Company
Treatments:
Pioglitazone
Rosiglitazone